CELLARITYX
LIVE

Serial Number

97893946

Owner

Cellarity, Inc.

Attorney

Christina M. Licursi

Filing Date

Apr 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CELLARITYX Trademark

Serial Number: 97893946

CELLARITYX is a trademark filed by Cellarity, Inc. on April 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Cellarity, Inc. (24 trademarks)

Somerville, MA 02143

Entity Type: 03

Trademark Details

Filing Date

April 18, 2023

Registration Date

Not Registered

Published for Opposition

December 19, 2023

Goods & Services

Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases

Downloadable computer software involving the use of artificial intelligence technology for molecular design

Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks

Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 12, 2026 EX4G
SOU EXTENSION 4 FILED
Feb 12, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2025 EXRA
SOU EXTENSION 3 GRANTED
Aug 8, 2025 EX3G
SOU EXTENSION 3 FILED
Aug 8, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 8, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 10, 2025 EXRA
SOU EXTENSION 2 GRANTED
Feb 10, 2025 EX2G
SOU EXTENSION 2 FILED
Feb 10, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 10, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 9, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 9, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 9, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 13, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 16, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 2, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 2, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 2, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 7, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 21, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 12, 2023 NWOS